Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted Income from Continuing Operations of -$4.9 million for fiscal Q4 2026 (quarter ended Jun 30, 2026), compared with -$8.88 million a year earlier.
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), Neuphoria Therapeutics' Income from Continuing Operations came in at -$13.45 million.
- In prior fiscal years, Neuphoria Therapeutics' Income from Continuing Operations was -$369,632 in FY2025, -$15.49 million in FY2024, -$21.29 million in FY2023 and -$15.59 million in FY2022.
- Quarterly Income from Continuing Operations has run from a low of -$9.91 million in fiscal Q1 2026 to a high of $11.26 million in fiscal Q3 2025 over five years.
- According to Business Quant data, Income from Continuing Operations for the three prior fiscal quarters was -$505,063 (Q3 2026), $1.86 million (Q2 2026) and -$9.91 million (Q1 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Neuphoria Therapeutics | 443.79 Mn | 368.60 Mn | - | -4.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.90 Mn |
| Mar 31, 2026 | -505,063.00 |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -8.88 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | -804,787.00 |
| Jun 30, 2024 | -2.69 Mn |
| Mar 31, 2024 | -2.78 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |
API Access
Neuphoria Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();